{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:32:12Z","timestamp":1791063132998,"version":"4.1.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Increasing evidence suggests that altered immune function accompanies, and indeed may facilitate, cancer progression. In this study, we sought to determine the nature of, and cellular mechanisms underlying, changes in immune status during disease progression in a transgenic mouse model of prostate dysplasia. Immune cells in the tumor microenvironment, as well as in the secondary lymphoid tissues, displayed altered phenotypes. Although evidence of antitumor immunity was detected, there was a paradoxical decrease in the ability of T cells to proliferate in vitro at later stages of disease progression. Detailed analysis of the draining lumbar lymph nodes revealed an increased frequency and number of CD4+CD25+ T cells and an enhanced production of inhibitory cytokines, which correlated with impaired T-cell function. Functional studies confirmed a role for CD4+CD25+ regulatory T cells in suppressing T-cell proliferation as well as regulating the growth of transplanted prostate tumor cells. In addition, our studies show for the first time that anti-CD25 antibody treatment reduces, but does not prevent, tumor growth in a transgenic mouse model of prostate dysplasia. Taken together, this work provides compelling evidence that prostate tumor progression is accompanied by altered immune function and, moreover, that regulatory T cells play an important role in this process. These studies thus provide the impetus for development of specific and effective strategies to deplete regulatory T cells, or suppress their function, as an alternative or adjunct strategy for reducing tumor growth.<\/jats:p>","DOI":"10.1158\/0008-5472.can-04-3271","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T21:52:59Z","timestamp":1126821179000},"page":"2947-2955","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Altered Immunity Accompanies Disease Progression in a Mouse Model of Prostate Dysplasia"],"prefix":"10.1158","volume":"65","author":[{"given":"Amy H.","family":"Tien","sequence":"first","affiliation":[{"name":"1Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xu","sequence":"additional","affiliation":[{"name":"1Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl D.","family":"Helgason","sequence":"additional","affiliation":[{"name":"1Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; and"},{"name":"2Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"2022061621065926900_B1","doi-asserted-by":"crossref","unstructured":"Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev\u20082000; 14: 2410\u201334.","DOI":"10.1101\/gad.819500"},{"key":"2022061621065926900_B2","doi-asserted-by":"crossref","unstructured":"McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol Lett\u20082005; 96: 3\u20139.","DOI":"10.1016\/j.imlet.2004.06.009"},{"key":"2022061621065926900_B3","doi-asserted-by":"crossref","unstructured":"Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest\u20082003; 21: 873\u201386.","DOI":"10.1081\/CNV-120025091"},{"key":"2022061621065926900_B4","unstructured":"Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res\u20082001; 61: 6451\u20138."},{"key":"2022061621065926900_B5","doi-asserted-by":"crossref","unstructured":"Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med\u20082000; 6: 332\u20136.","DOI":"10.1038\/73193"},{"key":"2022061621065926900_B6","doi-asserted-by":"crossref","unstructured":"Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol\u20082001; 167: 7150\u20136.","DOI":"10.4049\/jimmunol.167.12.7150"},{"key":"2022061621065926900_B7","doi-asserted-by":"crossref","unstructured":"Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol\u20082000; 18: 45\u201373.","DOI":"10.1146\/annurev.immunol.18.1.245"},{"key":"2022061621065926900_B8","unstructured":"Carducci MA, DeWeese TL, Nelson WG, et al. Prostate cancer treatment strategies based on tumor-specific biological principles: future directions. Semin Oncol\u20081996; 23: 56\u201362."},{"key":"2022061621065926900_B9","doi-asserted-by":"crossref","unstructured":"Troy A, Davidson P, Atkinson C, Hart D. Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol\u20081998; 160: 214\u20139.","DOI":"10.1016\/S0022-5347(01)63093-3"},{"key":"2022061621065926900_B10","doi-asserted-by":"crossref","unstructured":"Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol\u20082000; 164: 1269\u201376.","DOI":"10.4049\/jimmunol.164.3.1269"},{"key":"2022061621065926900_B11","doi-asserted-by":"crossref","unstructured":"Pirtskhalaishvili G, Shurin GV, Gambotto A, et al. Transduction of dendritic cells with Bcl-xL increases their resistance to prostate cancer-induced apoptosis and antitumor effect in mice. J Immunol\u20082000; 165: 1956\u201364.","DOI":"10.4049\/jimmunol.165.4.1956"},{"key":"2022061621065926900_B12","doi-asserted-by":"crossref","unstructured":"Pirtskhalaishvili G, Shurin GV, Esche C, et al. Cytokine-mediated protection of human dendritic cells from prostate cancer-induced apoptosis is regulated by the Bcl-2 family of proteins. Br J Cancer\u20082000; 83: 506\u201313.","DOI":"10.1054\/bjoc.2000.1289"},{"key":"2022061621065926900_B13","doi-asserted-by":"crossref","unstructured":"Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol\u20082003; 21: 685\u2013711.","DOI":"10.1146\/annurev.immunol.21.120601.141040"},{"key":"2022061621065926900_B14","doi-asserted-by":"crossref","unstructured":"Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev\u20082003; 196: 125\u201346.","DOI":"10.1046\/j.1600-065X.2003.00079.x"},{"key":"2022061621065926900_B15","doi-asserted-by":"crossref","unstructured":"Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10\u2013producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med\u20082000; 192: 1213\u201322.","DOI":"10.1084\/jem.192.9.1213"},{"key":"2022061621065926900_B16","doi-asserted-by":"crossref","unstructured":"Oldenhove G, de Heusch M, Urbain-Vansanten G, et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J Exp Med\u20082003; 198: 259\u201366.","DOI":"10.1084\/jem.20030654"},{"key":"2022061621065926900_B17","unstructured":"Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non\u2013small cell lung cancer and late-stage ovarian cancer. Cancer Res\u20082001; 61: 4766\u201372."},{"key":"2022061621065926900_B18","doi-asserted-by":"crossref","unstructured":"Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol\u20082002; 169: 2756\u201361.","DOI":"10.4049\/jimmunol.169.5.2756"},{"key":"2022061621065926900_B19","unstructured":"Wolf AM, Wolf D, Steurer M, et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res\u20082003; 9: 606\u201312."},{"key":"2022061621065926900_B20","doi-asserted-by":"crossref","unstructured":"Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med\u20082004; 10: 942\u20139.","DOI":"10.1038\/nm1093"},{"key":"2022061621065926900_B21","doi-asserted-by":"crossref","unstructured":"Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother\u20082002; 25: 207\u201317.","DOI":"10.1097\/00002371-200205000-00003"},{"key":"2022061621065926900_B22","unstructured":"Onizuka S, Tawara I, Shimizu J, et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor \u03b1) monoclonal antibody. Cancer Res\u20081999; 59: 3128\u201333."},{"key":"2022061621065926900_B23","doi-asserted-by":"crossref","unstructured":"Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2\u2013transduced dendritic cells enhance the interferon \u03b1-induced, CD8(+) T-cell\u2013dependent immune defense of B16 melanoma. Cancer Res\u20082001; 61: 8643\u20136.","DOI":"10.1038\/sj.gt.3301521"},{"key":"2022061621065926900_B24","unstructured":"Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest\u20081998; 78: 319\u201333."},{"key":"2022061621065926900_B25","unstructured":"Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res\u20082001; 61: 2239\u201349."},{"key":"2022061621065926900_B26","unstructured":"Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res\u20081997; 57: 3325\u201330."},{"key":"2022061621065926900_B27","doi-asserted-by":"crossref","unstructured":"Ciavarra RP, Brown RR, Holterman DA, et al. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother\u20082003; 52: 535\u201345.","DOI":"10.1007\/s00262-003-0383-x"},{"key":"2022061621065926900_B28","doi-asserted-by":"crossref","unstructured":"Ciavarra RP, Holterman DA, Brown RR, et al. Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand\/CD40-ligand immunotherapy. J Immunother\u20082004; 27: 13\u201326.","DOI":"10.1097\/00002371-200401000-00002"},{"key":"2022061621065926900_B29","doi-asserted-by":"crossref","unstructured":"Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int J Cancer\u20081997; 72: 619\u201324.","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<619::AID-IJC12>3.0.CO;2-6"},{"key":"2022061621065926900_B30","doi-asserted-by":"crossref","unstructured":"Zheng Y, Manzotti CN, Liu M, et al. CD86 and CD80 differentially modulate the suppressive function of human regulatory T cells. J Immunol\u20082004; 172: 2778\u201384.","DOI":"10.4049\/jimmunol.172.5.2778"},{"key":"2022061621065926900_B31","doi-asserted-by":"crossref","unstructured":"Yamazaki S, Iyoda T, Tarbell K, et al. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med\u20082003; 198: 235\u201347.","DOI":"10.1084\/jem.20030422"},{"key":"2022061621065926900_B32","doi-asserted-by":"crossref","unstructured":"Aalamian M, Pirtskhalaishvili G, Nunez A, et al. Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate\u20082001; 46: 68\u201375.","DOI":"10.1002\/1097-0045(200101)46:1<68::AID-PROS1010>3.0.CO;2-2"},{"key":"2022061621065926900_B33","doi-asserted-by":"crossref","unstructured":"Aalamian M, Tourkova IL, Chatta GS, et al. Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol\u20082003; 170: 2026\u201330.","DOI":"10.1097\/01.ju.0000091264.46134.b7"},{"key":"2022061621065926900_B34","doi-asserted-by":"crossref","unstructured":"Tourkova IL, Yamabe K, Foster B, et al. Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate\u20082004; 59: 203\u201313.","DOI":"10.1002\/pros.10369"},{"key":"2022061621065926900_B35","doi-asserted-by":"crossref","unstructured":"Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med\u20082001; 194: 847\u201353.","DOI":"10.1084\/jem.194.6.847"},{"key":"2022061621065926900_B36","doi-asserted-by":"crossref","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med\u20082001; 194: 823\u201332.","DOI":"10.1084\/jem.194.6.823"},{"key":"2022061621065926900_B37","doi-asserted-by":"crossref","unstructured":"Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol\u20081999; 163: 5211\u20138.","DOI":"10.4049\/jimmunol.163.10.5211"},{"key":"2022061621065926900_B38","unstructured":"Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun\u20082002; 2: 1."},{"key":"2022061621065926900_B39","doi-asserted-by":"crossref","unstructured":"Antony PA, Restifo NP. Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother\u20082002; 25: 202\u20136.","DOI":"10.1097\/00002371-200205000-00002"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/7\/2947\/2541348\/2947-2955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/7\/2947\/2541348\/2947-2955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:51:48Z","timestamp":1683211908000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/7\/2947\/519149\/Altered-Immunity-Accompanies-Disease-Progression"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-04-3271","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}